New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)
The DOI matches its Crossref record; 16 of the 17 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare the efficacy and safety of new insulin glargine 300 units/mL (Gla-300) with glargine 100 units/mL (Gla-100) in people with type 2 diabetes using basal insulin (≥42 units/day) plus oral antihyperglycemic drugs (OADs). RESEARCH DESIGN AND METHODS: EDITION 2 was a multicenter, open-label, two-arm study. Adults receiving basal insulin plus OADs were randomized to Gla-300 or Gla-100 once daily for 6 months. The primary end point was change in HbA1c. The main secondary end point was percentage of participants with one or more nocturnal confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycemic events from week 9 to month 6. RESULTS: Randomized participants (n = 811) had a mean (SD) HbA1c of 8.24% (0.82) and BMI of 34.8 kg/m2 (6.4). Glycemic control improved similarly with both basal insulins; least squares mean (SD) reduction from baseline was −0.57% (0.09) for Gla-300 and −0.56% (0.09) for Gla-100 (mean difference −0.01% [95% CI −0.14 to 0.12]), with 10% higher dose of Gla-300. Less nocturnal confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycemia was observed with Gla-300 from week 9 to month 6 (relative risk 0.77 [95% CI 0.61–0.99]; P = 0.038) and during the first 8 weeks. Fewer nocturnal and any time (24 h) hypoglycemic events were reported during the entire 6-month period. Weight gain was lower with Gla-300 than with Gla-100 (P = 0.015). No between-treatment differences in safety parameters were identified. CONCLUSIONS: Gla-300 was as effective as Gla-100 and associated with a lower risk of hypoglycemia during the night and at any time of the day.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“but about 7% to 15% of insulin-treated persons with T2D experience at least 1 episode of hypoglycemia per year,1109 and 1% to 2% have severe hypoglycemia.1106,1108”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1106]
In the citing paper
“Hypoglycemia and weight gain are the most common adverse effects of insulin therapy.1106,1107”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1106]
In the citing paper
“U-300 glargine has a longer duration of action than U-100 glargine but modestly lower efficacy per unit administered (179-181).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [181]
Citations
Cites
Levey, A. S., Coresh, J., Balk, E., Kausz, A. T., Levin, A., Steffes, M. W., Hogg, R. J., Perrone, R. D., Lau, J., & Eknoyan, G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-2-200307150-00013 · Cited by 4,615 · cited 1×
“5 rapidly progressing diabetic retinopathy (which may likely require laser/surgical treatment during the study), end-stage renal disease (defined as those participants requiring dialysis or transplantation (12)), or clinically significant cardiac, hepatic, or other systemic disease.”
BackgroundBasal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479 · cited 3×
“3 Insulin glargine 100 U/mL (Gla-100) is a once-daily, long-acting basal insulin analog, which induces less hypoglycemia than neutral protamine Hagedorn (NPH) insulin (1).”
BackgroundDefining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Peyrot, M., Barnett, A. H., Meneghini, L. F., & Schumm‐Draeger, P. ‐. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03605.x · Cited by 655 · cited 1×
“adherence to the treatment regimen (7,8).”
Psychological Insulin Resistance in Patients With Type 2 Diabetes
Polonsky, W. H., Fisher, L., Guzman, S., Villa-Caballero, L., & Edelman, S. V. (2005) · Diabetes Care · doi:10.2337/diacare.28.10.2543 · Cited by 551
Becker, R. H. A., Dahmen, R., Bergmann, K., Lehmann, A., Jax, T., & Heise, T. (2015) · Diabetes Care · doi:10.2337/dc14-0006 · Cited by 407 · cited 2×
“After subcutaneous injection, Gla-300 has been shown to have smoother, more stable, and prolonged pharmacokinetic and pharmacodynamic profiles than Gla-100, resulting from an extended release of glargine from the subcutaneous depot (9).”
BackgroundRiddle, M. C., Bolli, G. B., Ziemen, M., Muehlen-Bartmer, I., Bizet, F., & Home, P. D. (2014) · Diabetes Care · doi:10.2337/dc14-0991 · Cited by 354
Self-citationInsulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes
Zinman, B., Philis-Tsimikas, A., Cariou, B., Handelsman, Y., Rodbard, H. W., Johansen, T., Endahl, L., Mathieu, C., & on behalf of the NN1250-3579 (BEGIN Once Long) Trial Investigators (2012) · Diabetes Care · doi:10.2337/dc12-1205 · Cited by 336
Bretzel, R. G., Nuber, U., Landgraf, W., Owens, D. R., Bradley, C., & Linn, T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60485-7 · Cited by 305 · cited 1×
“Its efficacy in achieving and maintaining target glycemic control and safety profile in terms of cardiovascular risk and cancer is well documented (1-6).”
Background
Cited by
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s009 · Cited by 972
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s009 · Cited by 914
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s009 · Cited by 851
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s009 · Cited by 739
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728
Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician
Blonde, L., Khunti, K., Harris, S. B., Meizinger, C., & Skolnik, N. S. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0805-y · Cited by 714
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s009 · Cited by 662
Update on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Bolli, G. B., Riddle, M. C., Bergenstal, R. M., Ziemen, M., Sestakauskas, K., Goyeau, H., Home, P. D., & on behalf of the EDITION 3 study investigators (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12438 · Cited by 301
“This increase in body weight tended to be less with Gla-300 compared with Gla-100, consistent with the results of EDITION 2 [14], as well as those of EDITION 4 in subjects with type 1 diabetes [24].”
BackgroundResultInfluentialSelf-citation9. pharmacologic approaches to glycemic treatment: standards of care in diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s009 · Cited by 263
Ritzel, R., Roussel, R., Bolli, G. B., Vinet, L., Brulle‐Wohlhueter, C., Glezer, S., & Yki‐Järvinen, H. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12485 · Cited by 236
Self-citationHome, P. D., Bergenstal, R. M., Bolli, G. B., Ziemen, M., Rojeski, M., Espinasse, M., & Riddle, M. C. (2015) · Diabetes Care · doi:10.2337/dc15-0249 · Cited by 221
Self-citationWysham, C., Bhargava, A., Chaykin, L., de la Rosa, R., Handelsman, Y., Troelsen, L. N., Kvist, K., & Norwood, P. (2017) · JAMA · doi:10.1001/jama.2017.7117 · Cited by 221
Yki‐Järvinen, H., Bergenstal, R. M., Bolli, G. B., Ziemen, M., Wardecki, M., Muehlen‐Bartmer, I., Maroccia, M., & Riddle, M. C. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12532 · Cited by 131
Self-citationLow within‐ and between‐day variability in exposure to new insulin glargine 300 U/ml
Becker, R. H. A., Nowotny, I., Teichert, L., Bergmann, K., & Kapitza, C. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12416 · Cited by 125
Bergenstal, R. M., Bailey, T. S., Rodbard, D., Ziemen, M., Guo, H., Muehlen-Bartmer, I., & Ahmann, A. J. (2017) · Diabetes Care · doi:10.2337/dc16-0684 · Cited by 122
Self-citationDoyle-Delgado, K., Chamberlain, J. J., Shubrook, J. H., Skolnik, N., & Trujillo, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-2470 · Cited by 111
Riddle, M. C., Yki‐Järvinen, H., Bolli, G. B., Ziemen, M., Muehlen‐Bartmer, I., Cissokho, S., & Home, P. D. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12472 · Cited by 110
“This programme compared the efficacy and safety of Gla-300 with that of Gla-100 in people with T2DM using basal-bolus insulin (EDITION 1) [6], people with T2DM using basal insulin and oral antihyperglycaemic drugs (EDITION 2) [7], and insulin-naïve people with T2DM (EDITION 3) [8].”
MethodSelf-citationNew forms of insulin and insulin therapies for the treatment of type 2 diabetes
Cahn, A., Miccoli, R., Dardano, A., & Prato, S. D. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00097-2 · Cited by 114
Terauchi, Y., Koyama, M., Cheng, X., Takahashi, Y., Riddle, M. C., Bolli, G. B., & Hirose, T. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12618 · Cited by 106
Self-citationShiramoto, M., Eto, T., Irie, S., Fukuzaki, A., Teichert, L., Tillner, J., Takahashi, Y., Koyama, M., Dahmen, R., Heise, T., et al. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12415 · Cited by 95
Home, P. D. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12501 · Cited by 90
Matsuhisa, M., Koyama, M., Cheng, X., Takahashi, Y., Riddle, M. C., Bolli, G. B., Hirose, T., & on behalf of the EDITION JP 1 study group (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12619 · Cited by 85
Self-citationThe past, present, and future of basal insulins
Pettus, J., Santos Cavaiola, T., Tamborlane, W. V., & Edelman, S. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2763 · Cited by 80
Ritzel, R., Roussel, R., Giaccari, A., Vora, J., Brulle‐Wohlhueter, C., & Yki‐Järvinen, H. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13105 · Cited by 73
Self-citationon behalf of the CONCLUDE Study Group, Philis-Tsimikas, A., Klonoff, D. C., Khunti, K., Bajaj, H. S., Leiter, L. A., Hansen, M. V., Troelsen, L. N., Ladelund, S., Heller, S., et al. (2020) · Diabetologia · doi:10.1007/s00125-019-05080-9 · Cited by 73
Sullivan, S. D., Bailey, T. S., Roussel, R., Zhou, F. L., Bosnyak, Z., Preblick, R., Westerbacka, J., Gupta, R. A., & Blonde, L. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13345 · Cited by 73
Freemantle, N., Chou, E., Frois, C., Zhuo, D., Lehmacher, W., Vlajnic, A., Wang, H., Chung, H.-W., Zhang, Q., Wu, E., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-009421 · Cited by 60
Ritzel, R. A., Harris, S. B., Baron, H. L., Florez, H. J., Roussel, R., Espinasse, M., Muehlen-Bartmer, I., Zhang, N., Bertolini, M., Brulle-Wohlhueter, C., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0168 · Cited by 58
Self-citationConcentrated insulins: the new basal insulins
Davis, S. N., Lamos, E. M., & Younk, L. M. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s99855 · Cited by 61
“48 Hypoglycemia When glargine U300 was studied in individuals with T1DM, nocturnal or any-time hypoglycemia was similar or reduced when compared with glargine U100.”
InfluentialCheng, A. Y. Y., Patel, D. K., Reid, T. S., & Wyne, K. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00925-6 · Cited by 51
Riddle, M. C., Bolli, G. B., Home, P. D., Bergenstal, R. M., Ziemen, M., Muehlen-Bartmer, I., Wardecki, M., Vinet, L., Jeandidier, N., & Yki-Järvinen, H. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0290 · Cited by 50
Self-citationBolli, G. B., Riddle, M. C., Bergenstal, R. M., Wardęcki, M., Goyeau, H., & Home, P. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.04.007 · Cited by 50
Self-citationRoussel, R., Ritzel, R. A., Corfec, E. B., Balkau, B., & Rosenstock, J. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.02.002 · Cited by 50
Porcellati, F., Lucidi, P., Candeloro, P., Cioli, P., Marinelli Andreoli, A., Curti, G., Bolli, G. B., & Fanelli, C. G. (2019) · Diabetes Care · doi:10.2337/dc18-0706 · Cited by 45
Pasquel, F. J., Lansang, M. C., Khowaja, A., Urrutia, M. A., Cardona, S., Albury, B., Galindo, R. J., Fayfman, M., Davis, G., Migdal, A., et al. (2020) · Diabetes Care · doi:10.2337/dc19-1940 · Cited by 45
Concentrated insulins: Clinical update of therapeutic options
Umpierrez, G. E., Holt, E. H., Einhorn, D., & McGill, J. B. (2020) · Endocrine Practice · doi:10.4158/ep-2019-0607 · Cited by 44
Kawaguchi, Y., Sawa, J., Sakuma, N., & Kumeda, Y. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.12884 · Cited by 40
Goldman, J., Kapitza, C., Pettus, J., & Heise, T. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1335192 · Cited by 38
“In six, phase 3, multinational, open-label non-inferiority studies in patients with T1D and T2D, Gla-300 consistently showed comparable glycemic control to Gla-100 [61-68].”
BackgroundHassanein, M. M., Büyükbeşe, M. A., Malek, R., Pilorget, V., Naqvi, M., Berthou, B., Shaltout, I., & Sahay, R. K. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108189 · Cited by 41
Meneghini, L. F., Mauricio, D., Orsi, E., Lalic, N. M., Cali, A. M. G., Westerbacka, J., Stella, P., Candelas, D., Pilorget, V., Perfetti, R., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13673 · Cited by 36
“It is of interest that the rates of symptomatic hypoglycaemia during the study period in both newly initiated (14%) and previously initiated (18%) participants were lower than predicted (45% and 20%, respectively) based on conservative estimates from previous randomized clinical trials.(28,33) This suggests that such…”
ResultThe importance of the initial period of basal insulin titration in people with diabetes
Khunti, K., Giorgino, F., Berard, L., Mauricio, D., & Harris, S. B. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13946 · Cited by 41
Vargas‐Uricoechea, H. (2018) · Journal of Diabetes Research · doi:10.1155/2018/2052101 · Cited by 41
New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus
Goldman, J., & White, J. R. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015597915 · Cited by 36
Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus
Blair, H. A., & Keating, G. M. (2016) · Drugs · doi:10.1007/s40265-016-0541-z · Cited by 35
Owens, D. R. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1202916 · Cited by 35
“Across the trials, changes in variability in preinjection self-monitored plasma glucose (SMPG), and the 8-point SMPG profile were generally similar in patients receiving Gla-300 and those receiving Ga-100 [12,14,26].”
BackgroundMethodResultInfluentialBailey, T. S., Wu, J., Zhou, F. L., Gupta, R. A., Menon, A. A., Berhanu, P., Westerbacka, J., Vleet, J. V., & Blonde, L. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13818 · Cited by 35
Owens, D. R., Bailey, T. S., Fanelli, C. G., Yale, J., & Bolli, G. B. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.11.004 · Cited by 36
“These studies demonstrated comparable glycaemic control with Gla-300 and Gla-100, together with a reduced risk of hypoglycaemia with Gla-300, predominantly, but not exclusively, at night and despite a higher Gla-300 dose in T2DM [17,24,26,27,31,32].”
BackgroundResultInfluentialYale, J., Berard, L., Groleau, M., Javadi, P., Stewart, J. A., & Harris, S. B. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.06.007 · Cited by 32
Cavaiola, T. S., Kiriakov, Y., & Reid, T. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.11.015 · Cited by 33
New Long-Acting Basal Insulins: Does Benefit Outweigh Cost?
Standl, E., & Owen, D. R. (2016) · Diabetes Care · doi:10.2337/dcs15-3011 · Cited by 35
Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
Lau, I. T., Lee, K. F., So, W. Y., Tan, K. C. B., & Yeung, M. W. (2017) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s131358 · Cited by 33
Yamabe, M., Kuroda, M., Hirosawa, Y., Kamino, H., Ohno, H., & Yoneda, M. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.12894 · Cited by 29
Forst, T. M., Choudhary, P., Schneider, D., Linetzky, B., & Pozzilli, P. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3418 · Cited by 34
Yuan, X., Guo, X., Zhang, J., Dong, X., Lu, Y., Pang, W., Gu, S., Niemoeller, E., Lin, P., Nian, G., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14803 · Cited by 31
Mannucci, E., Caiulo, C., Naletto, L., Madama, G., & Monami, M. (2021) · Endocrine · doi:10.1007/s12020-021-02889-6 · Cited by 30
Matsuhisa, M., Koyama, M., Cheng, X., Sumi, M., Riddle, M. C., Bolli, G. B., & Hirose, T. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.10.002 · Cited by 31
Self-citationTerauchi, Y., Koyama, M., Cheng, X., Sumi, M., Riddle, M. C., Bolli, G. B., & Hirose, T. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.03.001 · Cited by 30
Self-citationDanne, T., Tamborlane, W. V., Malievskiy, O. A., Franco, D. R., Kawamura, T., Demissie, M., Niemoeller, E., Goyeau, H., Wardęcki, M., & Battelino, T. (2020) · Diabetes Care · doi:10.2337/dc19-1926 · Cited by 31
Hassanein, M. M., Hanif, W., Malek, R., & Jabbar, A. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108584 · Cited by 28
Yale, J., Aroda, V. R., Charbonnel, B. H., Sinclair, A. J., Trescolí, C., Cahn, A., Bigot, G., Merino‐Trigo, A., Brulle-Wohlhueter, C., Bolli, G. B., et al. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.10.002 · Cited by 28
New Insulins and New Aspects in Insulin Delivery
Woo, V. C. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.04.006 · Cited by 29
Diabetes Treatment in the Elderly: Incorporating Geriatrics, Technology, and Functional Medicine
Valencia, W. M., Botros, D., Vera-Nunez, M. A., & Dang, S. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1052-y · Cited by 29
Insulin Matters: A Practical Approach to Basal Insulin Management in Type 2 Diabetes
Berard, L., Antonishyn, N., Arcudi, K., Blunden, S., CHENG, A. Y. Y., Goldenberg, R., Harris, S. B., Jones, S., Mehan, U., Morrell, J., et al. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0375-7 · Cited by 26
Gupta, S., Wang, H., SKOLNIK, N., Tong, L., Liebert, R., Lee, L. K., Stella, P., Cali, A. M. G., & Preblick, R. (2018) · Advances in Therapy · doi:10.1007/s12325-017-0651-3 · Cited by 26
Jinnouchi, H., Koyama, M., Amano, A., Takahashi, Y., Yoshida, A., Hieshima, K., Sugiyama, S., Kurinami, N., Jinnouchi, T., & Becker, R. H. A. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0115-1 · Cited by 25
Kerr, D. E., Edelman, S. V., Vespasiani, G., & Khunti, K. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.04.006 · Cited by 26
Tien, K., Hung, Y., Chen, J., Chen, C., Wang, C., Hwu, C., Huang, Y., Hsiao, P., Tu, S., Wang, C., et al. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12984 · Cited by 24
Ji, L., Kang, E. S., Dong, X., Li, L., Yuan, G., Shang, S., Niemoeller, E., & EDITION AP trial investigators (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13936 · Cited by 24
“Incidence of any, documented, and severe or confirmed nocturnal hypoglycaemia was lower during the first 12 weeks compared with Gla-100.”
BackgroundMethodResultInfluentialWoo, V. C. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.01.007 · Cited by 23
Holmes, R. S., Crabtree, E. A., & McDonagh, M. S. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13614 · Cited by 24
Escalada, J., Halimi, S., Senior, P. A., Bonnemaire, M., Cali, A. M. G., Melas‐Melt, L., Karalliedde, J. J., & Ritzel, R. A. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13470 · Cited by 23
György, J., Gaál, Z., Gerő, L., Hídvégi, T., Kempler, P., Winkler, G., & Wittmann, I. (2017) · Diabetologia Hungarica · doi:10.24121/dh.2017.1 · Cited by 39
New Long-Acting Insulin Analogs: From Clamp Studies to Clinical Practice
Bolli, G. B., & DeVries, J. H. (2015) · Diabetes Care · doi:10.2337/dc14-2314 · Cited by 28
Philis‐Tsimikas, A., STRATTON, I. M., Troelsen, L. N., Bak, B. A., & Leiter, L. A. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819841585 · Cited by 22
Bedros, J. R., Jermendy, G., Gaál, Z., Gerő, L., Hídvégi, T., Kempler, P., Lengyel, C., Várkonyi, T. T., Winkler, G., & Wittmann, I. (2023) · Diabetologia Hungarica · doi:10.24121/dh.2023.20 · Cited by 21
Cheng, A. Y. Y., Wong, J., Freemantle, N., Acharya, S. H., & Ekinci, E. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00925-8 · Cited by 20
Glargine-300: An updated literature review on randomized controlled trials and real-world studies
Ghosh, S. K., & GHOSH, R. (2020) · World Journal of Diabetes · doi:10.4239/wjd.v11.i4.100 · Cited by 22
Consenso sobre tratamiento con insulina en la diabetes tipo 2
Borrás, J. A. G., Escalada, J., Mata‐Cases, M., Peralta, F. G., Menéndez, S. A., García, D. F., Millán, C. O., Guisasola, F. Á., García, J. C. F., Loiola, P. E., et al. (2018) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2018.01.002 · Cited by 25
Kawaguchi, Y., Sawa, J., Hamai, C., & Kumeda, Y. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0654-y · Cited by 20
Freemantle, N., Mauricio, D., Giaccari, A., Bailey, T. S., Roussel, R., Franco, D. R., Berthou, B., Pilorget, V., Westerbacka, J., Bosnyák, Z., et al. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1708287 · Cited by 19
Conget, I., Mangas, M. Á., Morales, C., Caro, J., Giménez, M., Borrell, M., & Delgado, E. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01153-4 · Cited by 20
Galstyan, G. R., Tirosh, A., Vargas‐Uricoechea, H., Mabunay, M. A., Coudert, M., Naqvi, M., Pilorget, V., & Khan, N. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01266-4 · Cited by 19
Challenges and unmet needs in basal insulin therapy: lessons from the Asian experience
Chan, W. B., Chen, J.-F., Goh, S., Vũ, T. T. H., Isip-Tan, I. T., Mudjanarko, S. W., Bajpai, S., Mabunay, M. A., & Bunnag, P. (2017) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s143046 · Cited by 19
Insulin depot absorption modeling and pharmacokinetic simulation with insulin glargine 300 U/mL
Lindauer, K., & Becker, R. H. A. (2018) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cp203269 · Cited by 18
“In randomized clinical trials in which basal insulin dose was titrated seeking a predefined self-monitored plasma glucose target, this translated into less hypoglycemia [10, 11, 12, 13, 14, 15, 16] and apparently lower glycemic fluctuation with the same efficacy in terms of HbA 1c reduction [17].”
Insulin glargine 300 U/ml for the treatment of feline diabetes mellitus
Linari, G., Fleeman, L. M., Gilor, C., Giacomelli, L., & Fracassi, F. (2021) · Journal of Feline Medicine and Surgery · doi:10.1177/1098612x211013018 · Cited by 20
Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300 U/mL
Clements, J. N., Threatt, T. B., Ward, E. D., & Shealy, K. M. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0464-6 · Cited by 19
DAILEY, G. E., & Lavernia, F. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12531 · Cited by 17
Concepts and clinical use of ultra-long basal insulin
Eliaschewitz, F. G., & Barreto, T. (2016) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-015-0117-1 · Cited by 20
Landgraf, W., Bigot, G., Hess, S., Asplund, O., Groop, L., Ahlqvist, E., Käräjämäki, A., Owens, D. R., Frier, B. M., & Bolli, G. B. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110012 · Cited by 18
Klonoff, D. C., Nayberg, I., Erbstein, F., Cali, A. M. G., Brulle-Wohlhueter, C., & Haak, T. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815586219 · Cited by 17
An Overview of Concentrated Insulin Products
Painter, N. A., & Sisson, E. M. (2016) · Diabetes Spectrum · doi:10.2337/diaspect.29.3.136 · Cited by 17
Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges
Blumer, I. R., & CLEMENT, M. A. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.09.020 · Cited by 18
Abitbol, A., Brown, R. E., Jiandani, D., Sauriol, L., & Aronson, R. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.04.012 · Cited by 17
Insulin glargine 300 units/mL: A new basal insulin product for diabetes mellitus
Clements, J. N., & Bello, L. (2016) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp150174 · Cited by 18
Munshi, M. N., Gill, J., Chao, J., Nikonova, E., & Patel, M. (2017) · Endocrine Practice · doi:10.4158/ep171922.or · Cited by 17
Metadata
- Authors
- Yki-Järvinen, H., Bergenstal, R., Ziemen, M., Wardecki, M., Muehlen-Bartmer, I., Boelle, E., & Riddle, M. C.
- Affiliations
- Department of Medicine, University of Helsinki, and Minerva Foundation Institute for Medical Research, Helsinki, Finland
- Park Nicollet Health Services (US)
- Sanofi (Germany) (DE)
- Sanofi, Warsaw, Poland
- Sanofi, Paris, France
- Oregon Health & Science University (US)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-11-08
- Volume
- 37
- Issue
- 12
- Pages
- 3235-3243
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4230570152
- Cited by
- 274
- References
- 17
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 18 · 2023: 7 · 2022: 19 · 2021: 15 · 2020: 29 · 2019: 29 · 2018: 47 · 2017: 33 · 2016: 40 · 2015: 23 · 2014: 2
- FWCI
- 26.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin glargine, type 2 diabetes, basal insulin, oral antidiabetic drugs, glycemic control, HbA1c, hypoglycemia, nocturnal hypoglycemia, weight gain, insulin dose reduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.